Metabolic · 10 min read · Published September 8, 2026

Oral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming

The three approved GLP-1 pills, why a peptide pill needs an empty stomach and a small molecule does not, the trial numbers behind each approval (OASIS 4, ATTAIN-1, PIONEER), the boxed warning they all carry, and the pipeline: aleniglipron, elecoglipron, HRS-7535, and the drug Pfizer walked away from.

Which GLP-1 pills are approved in 2026?

Three in the United States as of September 2026. Rybelsus, oral semaglutide for type 2 diabetes, approved September 20, 2019. The Wegovy pill, oral semaglutide 25 mg for weight management and cardiovascular risk reduction, approved December 22, 2025. Foundayo, orforglipron, the first small-molecule GLP-1 pill for weight management, approved April 1, 2026. Everything else is investigational.

Until December 2025 the only GLP-1 you could swallow was a diabetes drug, and it came with fasting instructions. Two approvals in four months changed that, and they represent two different chemistries with different rules. This article separates them, puts every trial number next to its trial and duration, and lists what is behind them. Profiles: semaglutide, orforglipron.

Why does a peptide pill need an empty stomach and a small molecule does not?

Semaglutide is a peptide that stomach enzymes would digest. Oral semaglutide is co-formulated with SNAC, a salt that lets the peptide cross the stomach lining. That only works with nothing else in the stomach, hence the label: empty stomach, up to 4 ounces of water, wait 30 minutes. Orforglipron is a non-peptide small molecule taken with or without food.

The SNAC mechanism was worked out in 2018: the tablet dissolves against the stomach wall, SNAC buffers the acid and increases the peptide's passage through cells, and absorption happens in the stomach rather than the intestine (Buckley et al., 2018). It is clever, fragile chemistry. Food, other liquids or other pills taken at the same time interfere, which is why the Wegovy tablet label specifies once daily in the morning on an empty stomach with water up to 4 ounces, swallowed whole, and at least 30 minutes before eating, drinking anything else or taking other oral medicines (FDA label, Wegovy tablets, December 2025). Orforglipron was designed from the start as a small molecule that binds the GLP-1 receptor without being a peptide; its label reads once daily, with or without food (FDA label, Foundayo, April 2026). That single line is most of Foundayo's practical case.

What did the trials behind each approval show?

OASIS 4 (n=307, 64 weeks): oral semaglutide 25 mg gave 13.6 percent weight loss versus 2.2 percent for placebo, or 16.6 versus 2.7 percent on treatment. ATTAIN-1 (n=3,127, 72 weeks): orforglipron 36 mg gave 11.2 versus 2.1 percent, or 12.4 versus 0.9 percent on treatment. PIONEER 1 (n=703, 26 weeks): oral semaglutide 14 mg lowered HbA1c 1.1 points.

Two cautions when reading the table. The oral semaglutide and orforglipron numbers come from different trials with different lengths and populations; the only fair statement is that in their own trials the semaglutide pill produced more weight loss than the orforglipron pill (NEJM, OASIS 4; NEJM, ATTAIN-1). And the Foundayo tablets are labeled 0.8 to 17.2 mg while the ATTAIN-1 paper reports 6, 12 and 36 mg, so the numbers on the box will not match the numbers in the paper. Rybelsus, approved on ten PIONEER trials in 9,543 people, remains a diabetes drug only (Diabetes Care, PIONEER 1).

What is the boxed warning on the GLP-1 pills?

Risk of thyroid C-cell tumors. Semaglutide causes these tumors in rodents; whether it does in humans is unknown. Orforglipron is not active in rodents and did not produce tumors, but its label carries the same warning as a class effect. Both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.

The Foundayo boxed warning is unusual in stating plainly that the drug did not cause the rodent tumors, then applying the warning anyway because it activates the human GLP-1 receptor. Beyond the box, both labels list acute pancreatitis, gallbladder disease, acute kidney injury from dehydration, severe gastrointestinal reactions, hypoglycemia with insulin or sulfonylureas, and pulmonary aspiration under anesthesia. Foundayo adds CYP3A4 interactions (a maximum of 9 mg with strong inhibitors) and a note that it delays gastric emptying enough to affect other oral drugs. In ATTAIN-1 nausea occurred in 33.7 percent on 36 mg versus 10.4 percent on placebo, and vomiting in 24.0 versus 3.5 percent (Eli Lilly, April 2026). Pills do not escape the class's gut effects; they only change how you take them.

Which oral GLP-1s are coming next?

Three small molecules have Phase 3 plans. Aleniglipron reported 16.3 percent placebo-adjusted weight loss at 44 weeks on 180 mg (ACCESS II, n=85, March 2026). Elecoglipron reached up to 10.5 percent versus 0.6 percent in the 36-week VISTA Phase 2b (n=310). HRS-7535 met two Chinese Phase 3 endpoints in July 2026 with 10.9 percent at 44 weeks.

Aleniglipron's figure is placebo-adjusted, which typically runs 2 to 3 points below the raw means used for the approved drugs, but even so it is above orforglipron's 72-week result at a shorter duration (Structure Therapeutics, March 2026). Elecoglipron's VISTA data were published in the Lancet in 2026 (Lancet, VISTA), and HRS-7535's Chinese trials reported treatment discontinuation for adverse events of 3.1 to 4.1 percent versus 2.7 percent on placebo, with no liver signal (Kailera, July 2026). That last point matters because of danuglipron.

What happened to danuglipron?

Pfizer discontinued it on April 14, 2025. Its once-daily formulation had met its pharmacokinetic targets, but one asymptomatic participant in a dose-optimization study developed potential drug-induced liver injury that resolved on stopping. Liver enzyme elevations across the 1,400-plus-participant database were in line with the class, but Pfizer and regulators judged the single case enough to stop.

Danuglipron is the reminder that small-molecule GLP-1s are new chemistry. Peptides like semaglutide are broken down into amino acids; a synthetic small molecule is metabolized by the liver, and liver safety has to be established drug by drug (Pfizer, April 2025). Orforglipron's 3,127-person trial and the Chinese HRS-7535 program showed no such signal, and Pfizer replaced danuglipron by buying Metsera and its injectable berobenatide. For the injectable landscape see the 2026 GLP-1 field guide.

The bottom line

In 2026 the choice among GLP-1 pills is between a peptide that works better in its trial but demands a fasting ritual, and a small molecule that fits into a normal morning but produced less weight loss in its trial. Both sit below the injectables by a wide margin. The next wave, led by aleniglipron, may close that gap, and the class's liver safety will be watched drug by drug because of what happened to danuglipron.